BackBiogen Overview
Biogen Inc

Biogen Target Price

Analysts' average 12-month price target for Biogen is $240.

Get informed when a big investor buys or sells

+ Follow

Share Price

$220.83

Average Target Price

$240.208.8% upside

20 analysts in the last 4 months

High: $300 | Low: $157

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-03Piper Sandler$24510.9% upsideOpen
2026-08-25RBC Capital$26017.7% upsideOpen
2026-08-13Wolfe Research$30035.9% upsideOpen
2026-07-30Morgan StanleyTerence Flynn$2314.6% upsideOpen
2026-07-30RBC Capital$2408.7% upsideOpen
2026-07-30UBS$2408.7% upsideOpen
2026-07-30Canaccord Genuity$24812.3% upsideOpen
2026-07-30H.C. Wainwright$25113.7% upsideOpen
2026-07-29OppenheimerJay Olson$30035.9% upsideOpen
2026-07-21GuggenheimYatin Suneja$28026.8% upsideOpen
2026-07-13Wedbush$2019% downsideOpen
2026-07-13Truist Financial$2356.4% upsideOpen
2026-07-08Morgan StanleyTerence Flynn$2220.5% upsideOpen
2026-07-07RBC Capital$2429.6% upsideOpen
2026-07-06HSBCMorten Herholdt$15728.9% downsideOpen
2026-06-18Morgan Stanley$2241.4% upsideOpen
2026-06-15Mizuho SecuritiesSalim Syed$2210.1% upsideOpen
2026-06-08Needham$25515.5% upsideOpen
2026-05-27RBC CapitalBrian Abrahams$2272.8% upsideOpen
2026-05-15Piper Sandler$2251.9% upsideOpen
2026-04-30Morgan Stanley$2066.7% downsideOpen
2026-04-30Guggenheim$26017.7% upsideOpen
2026-04-30Wedbush$19611.2% downsideOpen
2026-04-30RBC CapitalBrian Abrahams$2220.5% upsideOpen
2026-04-20Wells FargoMohit Bansal$25013.2% upsideOpen
2026-04-14Piper Sandler$2143.1% downsideOpen
2026-04-10Morgan Stanley$2009.4% downsideOpen
2026-02-19BarclaysEmily Field$18516.2% downsideOpen
2026-02-11Mizuho Securities$2366.9% upsideOpen
2026-02-10WedbushLaura Chico$18715.3% downsideOpen
2026-02-09RBC Capital$2335.5% upsideOpen
2026-02-09Wolfe Research$2314.6% upsideOpen
2026-02-09Tudor PickeringWilliam Pickering$2019% downsideOpen
2026-02-09GuggenheimYatin Suneja$24611.4% upsideOpen
2026-02-09Piper Sandler$17719.8% downsideOpen
2026-02-09Canaccord Genuity$2304.2% upsideOpen
2026-02-09Truist FinancialDanielle Brill$19312.6% downsideOpen
2026-02-09H.C. WainwrightAndrew Fein$2283.2% upsideOpen
2026-02-09Wolfe Research$2152.6% downsideOpen
2026-02-08Wells Fargo$2009.4% downsideOpen
2026-02-08Morgan StanleyTerence Flynn$19014% downsideOpen
2026-02-06BMO CapitalEvan Seigerman$19611.2% downsideOpen
2026-02-03Bernstein$19113.5% downsideOpen
2026-01-30OppenheimerJay Olson$2251.9% upsideOpen
2026-01-08Goldman SachsSalveen Richter$2251.9% upsideOpen
2026-01-08Truist Financial$19014% downsideOpen
2026-01-06UBS$18516.2% downsideOpen
2025-12-12Morgan StanleyTerence Flynn$15629.4% downsideOpen
2025-12-10HSBC$14335.2% downsideOpen
2025-11-21Piper Sandler$15728.9% downsideOpen

Biogen (BIIB) FAQ

The latest target price for BIIB is $240. Investors often review this figure alongside Biogen's historical trend and sector peers before judging valuation or financial health.

Biogen trades near $220.83 while the consensus target sits at $240 (8.8% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting BIIB's target price ($240), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Biogen's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.